sb 203580 has been researched along with ro 5-3335 in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (ro 5-3335) | Trials (ro 5-3335) | Recent Studies (post-2010) (ro 5-3335) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 26 | 0 | 1 |
| Protein | Taxonomy | sb 203580 (IC50) | ro 5-3335 (IC50) |
|---|---|---|---|
| Protein Tat | Human immunodeficiency virus type 1 (CLONE 12) | 4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, H; Fujiwara, N; Kawakami, H; Nakajima, T; Ueda, Y | 1 |
1 other study(ies) available for sb 203580 and ro 5-3335
| Article | Year |
|---|---|
Novel piperidinylpyrimidine derivatives as inhibitors of HIV-1 LTR activation.
Topics: Animals; Anti-HIV Agents; Cells, Cultured; HIV Long Terminal Repeat; HIV-1; Humans; Inhibitory Concentration 50; Jurkat Cells; Mice; Pyrimidines; Transcriptional Activation; Tumor Necrosis Factor-alpha | 2008 |